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Abstract
Background: Procalcitonin (PCT) has become a commonly used serum inflammatory marker. Our aim was to describe
the kinetics and usefulness of serial post-operative PCT measurements to detect bacterial infection in a cohort of
children immediately after pediatric liver transplantation (pLT).
Methods: We performed a retrospective chart review of a cohort of pLT recipients with serial serum PCT measurements
in the first week following pLT. The presence of infection was determined on clinical and biological parameters. Normal
PCT was defined as < 0.5 (ng/ml).
Results: Thirty-nine patients underwent 41 pLT. PCT was measured daily during the first week post pLT. Values first
increased following surgery and then decreased, nearing 0.5 ng/ml at day seven. Peak PCT reached a median of 5.
61 ng/ml (IQR 3.83-10.8). Seventeen patients were considered to have an infection. There was no significant difference
in daily PCT or peak PCT between infected and non infected patients during the first post-operative week. AUC of ROC
curve for PCT during first week was never higher than 0.6.
Conclusions: We conclude that serial PCT measurements during the first week after pLT is not useful to identify
patients with bacterial infections. Rather, we propose that serum PCT may be useful after the first week post pLT.
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Background
Procalcitonin (PCT) is an acute phase protein used espe-
cially for prediction of bacterial infection. It was first
introduced as a biomarker in the early 90s, and since
then, its role as a useful inflammatory marker has been
confirmed [1–4]. It is produced by the liver, spleen, lung,
adrenal glands, monocytes and macrophages [1, 2, 5].
The classic cut-off for PCT in serum is 0.5 ng/ml. Its
serum levels can increase significantly during bacterial
infections and after surgery [6, 7]. In the latter case,
PCT levels decrease quickly during the first days, but
levels may take two weeks to return to baseline [2].
Interestingly, serum PCT does not rise in viral infections
or acute cellular rejection following pediatric liver trans-
plantation (pLT) [1, 8–10].
The liver is a major source of PCT. Therefore, predict-
ably, any hepatobiliary surgery will lead to a rise in serum
PCT levels [9, 11–14]. However, it is still frequently used
as a marker of infection in the early post-operative period
after pLT, and, in our center, is drawn once or twice daily
per protocol. Data on the utility of PCT early after
pediatric liver transplantation (pLT) are sparse and
contradictory.
In this retrospective study our primary aim was to
describe post-operative variations of PCT in children
after a pLT. Our secondary aim was to analyze the value
of PCT in distinguishing between patients with and
without post-operative bacterial infections in the first
seven days following pLT.
Methods
We performed a single center retrospective chart review
of children following pLT between 01/2010 and 04/2015
in our national liver transplantation center. Ethics
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committee approval and informed consent was obtained,
explicitly authorizing chart review studies for publication.
All children had at least one PCT measurement daily
during the first week after pLT. We excluded patients
without a single procalcitonin value and children for
whom a pathogen was identified in the organ preserva-
tion solution (N = 3). We recorded PCT levels drawn at
the same hour each day (morning labs) or PCT at any
other time if there was only one level available. We used
only one PCT value per day. Day 0 was defined as the
day the surgery was completed. The highest PCT value
of the week was termed ‘peak PCT’. PCT was measured
by electro-chemiluminescence immunoassay (Roche
Diagnostic AG, Rotkreuz, Switzerland) and expressed in
nanograms per milliliter (ng/mL). We compared PCT
data to C-reactive protein (CRP) levels. CRP was mea-
sured by immunoturbidimetry (Roche Diagnostic AG,
Rotkreuz, Switzerland). The highest CRP value of the
week was termed ‘peak CRP’.
We defined infection as any patient needing either
a change of antibiotic or addition of an antifungal during
the first week after pLT, based on clinical or laboratory
factors including: clinical deterioration, hemodynamic in-
stability, or positive blood- or urine cultures, tracheal aspi-
rates or sputum with or without other clinical signs of
infection.
We collected demographic and surgical data from
patient records to analyze their potential impact on in-
fection occurrence or their relationship to PCT level in
the post-op period. Diagnoses were classified as fol-
lows: biliary atresia, other cholestatic (PFIC, Alagille
syndrome, secondary biliary cirrhosis), acute liver fail-
ure, metabolic disease, immunological disease (overlap
syndrome, sclerosing cholangitis), tumor and other
(cystic fibrosis, cirrhosis of unknown origin). Graft
types were separated into whole liver and technical
variant for split and reduced liver.
Statistical analysis
For numerical variables, a Student T-test or a Wilcoxon
test was used depending on variable distribution. A Chi-
square test or a Fisher’s exact test were used to compare
categorical variables. Linear regression was used to find
impact of factor on peak PCT or PCT at 4th day. P-
values inferior to 0.05 were considered significant. Statis-
tical analyses were carried out with STATA software,
version 13.0 (StataCorp, College Station, TX, USA).
Results
Thirty-nine patients underwent 41 pLT. Two patients re-
ceived 2 pLT more than 6 months apart; these were
counted as separate events. One patient died 2 months
after pLT from multiple organ failure. The median age at
pLT was 37 months (IQR 10-144) with a median weight
of 13.6 kgs (IQR8.4-40).
All patients received a liver from a deceased donor,
either whole or a technical variant. Immunosuppression
for all patient included basiliximab induction followed
by tacrolimus as standard calcineurin inhibitor immuno-
suppression. Steroids were used in all but 4 patients who




received chemotherapy prior to transplant did not receive
basiliximab induction. All patients received broad spectrum
antibiotics intra-operatively and for 5 days following
surgery.
PCT kinetics following pLT
Daily post-transplant serum PCT values and peak PCT
are summarized in Fig. 1. Serum levels rised during post
operative days 0 and 1. Subsequently, PCT decreased to
approach the laboratory cut off of 0.5 ng/ml after seven
days. Only one patient had a PCT level below the limit
prior to the third post operative day.
PCT in patients treated for a bacterial infection
During the first seven days following pLT, seventeen
transplanted patients were clinically considered to have
a bacterial infection while 24 were not. Of the seventeen
patients, 6 had clinical signs of infections: 3 showed
signs suggestive of septic shock, 2 displayed a general
worsening and 1 had clinical and radiological evidence
of pneumonia. For the 11 others, all presented at least
one positive culture: 2 blood cultures, 4 urine cultures, 2
tracheal aspirates and 3 intra-abdominal samples collected
during transplant surgery. Most also presented with fever
and one was in septic shock immediately preceding trans-
plantation. Pseudomonas aeruginosa was the most fre-
quently identified pathogen (3/17). The following were
each identified in one patient: Staphylococcus epidermidis,
methicillin-sensible Staphylococcus aureus, Streptococcus
parasanguinis, Enterococcus faecalis, Escherichia Coli, En-
terobacter cloacae, Klebsiella pneumonia and oxytoca, Pro-
teus mirabilis, Stenotrophomonas maltophilia and
Candida tropicalis, (Additional file 1: Table S1). As shown
in table 1, there were no significant differences in
demographic or surgical variables between patients
with and without an infection. Figure 2 illustrates the
area under the curve for daily PCT during the first
week post LT, which did not reach statistical signifi-
cance. Figure 3 compares serum PCT levels between
the two groups. There were no significant differences
in daily serum PCT measurements or in peak PCT.
In both groups, serum values returned to normal be-
tween post operative days 5 and 6.
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Fig. 1 Daily and peak PCT values during the first week post liver transplantation. The median is indicated with a horizontal mark for each day.
PCT is expressed in nanogram per milliliter. PCT: procalcitonin
Table 1 Population characteristics for patients with infection (n = 17) and without infection (n = 24). Age, weight and peak serum
PCT levels are represented as median with interquartile range. Ischemia times are represented as mean with 95% confidence
interval. pLT: pediatric liver transplantation. ALF: acute liver failure. CI: confidence interval. IQR: interquartile range
No Infection N = 24 (%) Infection N = 17 (%) P value
DIAGNOSIS
Biliary atresia 12 (50) 6 (35.3) 0.35
Other cholestatic 1 (4.2) 1 (5.9) 1
ALF 3 (12.5) 1 (5.9) 0.60
Metabolic 3 (12.5) 1 (5.9) 0.60
Immunologic 1 (4.2) 2 (11.8) 0.56
Tumor 3 (12.5) 1 (5.9) 0.60
Other 1 (4.2) 5 (29.4) 0.06
Male 15 (62.5) 9 (52.9) 0.50
Female 9 (37.5) 8 (47.1) 0.50
Age at pLT (months) 26 (IQR 9-131) 45 (IQR 13-149) 0.80
Weight (kgs) 13.3 (IQR 7.6-38) 17 (IQR 8.5-40) 0.80
SURGICAL
Whole 10 (41.7) 10 (58.8) 0.27
Technical variant 14 (58.3) 7 (41.2) 0.27
Total ischemia time (min) 378 (CI 346-409) 416 (CI 355-476) 0.30
Warm ischemia time (min) 61 (CI 51-70) 54 (CI 43-63) 0.24
Peak PCT (ng/ml) 7.63 (IQR 3.6-10.3) 5.6 (IQR 3.9-10.8) 0.60
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By way of comparison, we also looked at CRP measure-
ments in both patient groups (Additional file 2: Figure S1).
Except for day 6, there were no statistical differences in
daily CRP values or peak CRP between the groups with
and without infection. In both groups, we observed an
initial rise followed by a steady decline during the first
week after pLT.
Recipient and surgical variables and PCT
We analyzed the following recipient and surgical vari-
ables for their potential association with increased serum
PCT in the early days following pLT: age or weight at
transplantation, diagnosis, and surgical- ischemia time
(warm, cold and total) and graft type. However, none of
these correlated with serum PCT levels at day 4 or peak
PCT, although there was a trend for patients having
received a technical variant (p = 0.052) to have a lower
peak PCT levels. We chose POD 4, because in the litera-
ture it is the earliest timepoint at which PCT has been
reported to be of some value after pLT [8].
One of the major differences between whole and split
grafts is the presence of a cut surface and thus a pro-
longed handling/dissection of the very organ that
produces PCT. We therefore performed a post-hoc ana-
lysis to compare patients with a whole liver to those with
a partial liver. Patients receiving partial grafts (technical
variants) were younger and lighter (p < 0.001). They also
had a significantly shorter total ischemia time (p = 0.02)
(Additional file 3: Table S2). Moreover, PCT values were
significantly different until the fifth post-operative day
according to transplantation type: day 1 p = 0.02, day 2
p = 0.009, day 3 p = 0.02, day 4 p = 0.03. On day 5, the p
value reached 0.47 and did not differ between graft type
thereafter. Peak PCT was also significantly higher in
whole graft recipients (p = 0.05).
Discussion
Serum PCT does not detect bacterial infection early post
pLT
In this study, we analyzed the kinetics of PCT during the
first week after pLT. In all patients serum PCT rose during
post-operative days 0 and 1 and returned to baseline by the
end of the first week. The general kinetics of post-operative
PCT were similar to other reports [9, 12, 15, 16]. After an
initial increase, PCT decreased to its baseline level at a dif-
ferent rate for each patient. In a report on PCT kinetics in
Fig. 2 ROC curve of PCT during the first week after the transplantation. AUC: area under the curve. PCT: procalcitonin. POD: post operative day
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lung transplantation, only 50% of patients had a PCT <
0.5 ng/ml after one week [17].
We also studied whether serum PCT levels were of
value in distinguishing pLT recipients with and without
early post-operative bacterial infections. In total, the two
groups did not differ in PCT kinetics or peak level in the
early post operative period, confirming the findings of
others [9, 12, 15]. We observed from our retrospective
chart review that PCT levels were seldom used in the
clinical decision to treat suspected infection. Rather,
clinical signs were the main criteria to guide decision-
making. In a recent report by Mandell et al, who also
used clinical criteria for infections in pediatric intensive
care, the authors concluded that PCT measurements did
not predict bacterial infections reliably enough to be
clinically useful [18].
The liver has a crucial role in PCT regulation, and
therefore it follows that major hepatic surgery can con-
tribute to upsetting its homeostasis [11, 14, 19]. Thus, it
is reasonable to assume that early post pLT perturba-
tions in serum PCT levels are both the product of the
surgery and of the immunological storm created by the
allograft. Together, these processes overshadow the
response of the new allograft (and of other cells that
produce PCT) to an infectious stimulus [14, 20]. The
magnitude of the immune stimulus is such that even in
hematopoietic stem cell transplantation, in which the
liver is in its native state, PCT seems to be a suboptimal
marker of infection [19].
Other groups proposed that PCT values were not of use
for the diagnosis of infection before POD 4 [8, 21, 22]. We
would like to extend the same recommendation by
suggesting that PCT is of little value prior to POD 5. We
proposed day 5 because PCT started to diminish at this
time, and there was no difference between graft type start-
ing on POD 5. Thus, prior to POD 5, it is imperative to
consider serum levels with clinical findings, while bearing
in mind that patients with whole grafts may display higher
serum values. Moreover, it is essential to keep in mind
that early after the procedure a normal level does not rule
out infection, something of importance if antimicrobial
regimen is being weaned.
In this small cohort, partial grafts were associated with
a lower peak PCT. The reasons for this novel finding are
unclear. One possibility is that technical variant grafts
had a significantly shorter total ischemia time than
whole organs, thereby impacting serum PCT values
known to rise in ischemia [14, 16, 19, 22–24]. On the
other hand, ischemia time was not significantly asso-
ciated with PCT in the linear regression, suggesting
that ischemia time alone does not solely explain the
difference. More likely is the fact that small grafts
were implanted into smaller children who received
proportionately more intra- and post- operative fluids
compared to older children thereby leading to a rela-
tive dilution of measurable PCT until day 5.
Other reports have suggested that recipients of grafts
from living donors displayed lower PCT levels than those
receiving grafts from deceased donors [16, 22]. Ischemia
time may have contributed to this difference [16]. Even if
we could not account for it, it is important to remember
that donor history has been shown to contribute signifi-
cantly to PCT levels [25]. Moreover, donor PCT was
shown to predict early cardiac graft failure [26, 27], some-
thing which we could not verify in the present study.
CRP is an acute phase protein; its level has been
reported to have a high sensitivity but low specificity to
detect inflammation triggered by surgery, transplantation
or numerous post-pLT complications [12, 28–30]. It has
been shown that CRP offers no advantage over PCT to
diagnose infection following liver transplantation [9]. Yet,
unlike PCT, peak CRP may help predict infection in the
setting of pLT [15]. Therefore, we analyzed CRP values,
but there was no difference between groups with and
without a clinically-suspected infection except on day 6.
In light of our findings, we performed a simple post-hoc
cost-benefit analysis. Most patients in our cohort had at
least 2 PCT levels drawn daily per protocol during the first
week post LT. Considering that every PCT level drawn be-
fore POD 5 was not useful, this amounted to 10 PCT
measurements per transplantation totaling 410 unneces-
sary PCT measurements in our cohort amounting to a
total USD 34000 for the length of the study. In other
Fig. 3 Mean daily and peak PCT values for the groups with and
without infection. PCT: procalcitonin. PCT is expressed in nanograms
per milliliter. PCT: procalcitonin. ALF: acute liver failure
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words, savings would amount to 840 USD per transplant.
Similarly, non-contributory daily CRP measurements to-
taled USD 4000. In total, combined with CRP costs, we
could have saved in excess of USD 38’000 by cutting back
on daily measurements of PCT and CRP during early
post-transplant follow-up, something we have now
implemented.
Limitations of the study
Our study was marred by several limitations. First, the
sample size was small, owing to the recent use of PCT in
our institution. Further, we did not have a daily PCT value
for all patients. Next, the definition of severe bacterial
infection was clinical and not based on extensive bacterio-
logical work up and proof. However, it was representative
of the clinical practice in a post-transplant intensive care
unit with acutely ill patients, under immunosuppressive
drugs. Moreover, this definition is also used in other
reports on PCT use in pediatric intensive care units [18].
Conclusion
In our small but representative cohort we have shown that
PCT was of little value in distinguishing patients with or
without severe bacterial infection in the first week post
pLT. Rather, it is possibly a valuable diagnostic tool be-
yond the first post-operative week because it regains its
normal value at the end of the first week. We recommend
the limited and cautious use of this costly test in the first
week follow up of post pLT patients.
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